Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
TON Strategy Co reported a net loss of $38.4 million for the nine months ended September 30, 2026, compared to a net income of $79.9 million in the prior year period. The company underwent a significant rebranding of its native digital asset from 'Toncoin' (TON) to 'Gram' (GRAM) effective June 8, 2026, and held approximately $348.5 million in GRAM assets as of the reporting date.
Contango Silver & Gold reported financial results for the quarter ended September 30, 2026, highlighted by its share of production from the Manh Choh mine totaling 7,333 ounces of gold and 5,349 ounces of silver. The company reported a net loss of $23.0 million for the quarter, primarily driven by expensed exploration across its portfolio of projects including Kitsault Valley and Lucky Shot. Management reaffirmed its 2026 production guidance of 40,000 gold equivalent ounces.
Term
Q3 2026
“The focus for the third quarter was to continue to advance and de-risk our portfolio of advanced-stage exploration projects. On the mining front at Manh Choh, the Peak Gold JV completed the transition from the north pit to the south pit while significant improvements were also made to the milling facility to accommodate the higher copper and total sulfur content of the high-grade sulfide ore.”
Rick Van Nieuwenhuyse, the Company’s Chief Executive Officer
“Operational enhancements continue to be made ahead of our fourth 2026 campaign, scheduled to commence in mid-November with anticipated production of 13,000 to 15,000 gold equivalent ounces net to Contango, keeping us on track to meet the lower end of 2026 production guidance of 40,000 gold equivalent ounces.”
Rick Van Nieuwenhuyse, the Company’s Chief Executive Officer
GigaCloud Technology announced that Sarah Anzalone will succeed Marshall Bernes as Head of Brand Center, effective November 30, 2026. Mr. Bernes is retiring from his corporate role but will remain on the Board of Directors until August 2027. Ms. Anzalone previously held senior product development roles at Simpli Home and eSolutions Furniture.
SS Innovations International Executive Compensation
SS Innovations International appointed Gary G. Lo as Chief Financial Officer and promoted Dr. Vishwa Srivastava to President. Mr. Lo's compensation includes a $400,000 base salary, a 50% target bonus, and 500,000 stock options with an exercise price of $2.11 per share.
OSR Health, Inc. reported a net loss of $6.38 million for the nine months ended September 30, 2026, an improvement from the $19.81 million loss in the prior year period. Total assets increased to $185.8 million, primarily driven by growth in intangible assets and goodwill following business combinations.
HeartSciences M&A Deal with Fortitude Mining Holdings, Inc.
HeartSciences Inc. filed an amendment to its 8-K regarding its pending merger with Fortitude Mining Holdings, Inc., a digital asset mining company. This filing provides updated interim financial statements and management's discussion for Fortitude for the nine months ended September 30, 2026. The update is a required step in the regulatory process to complete the previously announced business combination.
Virgin Galactic entered into a privately negotiated exchange agreement to retire approximately $12.5 million in aggregate principal amount of its 2.50% Convertible Senior Notes due 2027. In exchange for the notes, the company will issue shares of common stock determined by a volume-weighted average price (VWAP) formula over a two-day observation period. The transaction reduces the company's outstanding 2027 Notes by approximately 69.7%, leaving only $5.4 million in principal outstanding.
Evolution Metals & Technologies Corp. (EM&T) furnished a document released by YA II PN, Ltd. regarding the company's operational status and forward-looking strategy. The disclosure highlights EM&T's focus on rare earth and battery material recycling, smart factory automation, and the scaling of manufacturing capacity at its planned processing facilities.
Reinsurance Group of America EVP, Global Chief Risk Officer Jonathan Porter Sells $1.05M of Stock
Jonathan Porter, EVP, Global Chief Risk Officer, sold 3,852 shares of Reinsurance Group of America Inc at $271.53 a share, worth $1.05M in total on Nov 10, 2026. Shares held after the trade: 11,033 (-25.9%).
Shinhan Accounting Corporation resigned as OSR Health's independent auditor on November 6, 2026, citing overdue fees that created a potential independence threat. The company's previous financial reports included a going concern warning and identified material weaknesses in internal control over financial reporting. The Audit Committee has accepted the resignation and is currently seeking a successor accounting firm.
Suncrete, Inc. reported Q3 2026 financial results with revenue of $141.0 million, a 163% increase year-over-year, and a return to profitability with net income of $78 thousand. The company updated its full-year 2026 revenue guidance to a range of $408 million to $434 million, citing active Sunbelt markets tempered by project shifts and interest rate pressures.
Term
Q3 2026
“We are pleased with our performance in the third quarter, with revenue and Supplemental Adjusted EBITDA increasing 163% and 62%, respectively, compared to the second quarter which led to a 150 basis point improvement in Supplemental Adjusted EBITDA margin.”
Randall Edgar, Suncrete’s Chief Executive Officer
“Our team continues to build Suncrete’s scale”
Ned N. Fleming, III, the Company’s Executive Chairman
MetaVia Inc. reported a net loss of $13.8 million for the nine months ended September 30, 2026, compared to $11.0 million in the prior year, driven by increased research and development expenses. The company's cash position decreased to $8.8 million from $10.3 million at year-end 2025, while total stockholders' equity fell to $2.4 million.
Xenetic Biosciences provided a status update on its pending all-stock acquisition of Santersus AG, which is expected to transform the company into a clinical-stage entity focused on targeting neutrophil extracellular traps (NETs). The combined company will feature a pipeline with four first-in-class programs, including pivotal-stage programs in sepsis and SLE that have received FDA Breakthrough Device Designation.
Counterparty
Santersus AG
“This is a defining period for Xenetic as we work toward completing a transaction that we believe has the potential to fundamentally transform the Company's clinical development profile and long-term value proposition.”
James Parslow, Interim Chief Executive Officer and Chief Financial Officer
“We believe the complementary nature of NucleoCapture® and Xenetic's DNase platform provides a differentiated opportunity to address NETs through distinct mechanisms, potentially expanding the therapeutic reach of the combined platform.”
James Parslow, Interim Chief Executive Officer and Chief Financial Officer
Tandem Diabetes Care received FDA 510(k) clearance for Tandem Mobi, the world's first and only tubeless automated insulin delivery system with up to 7 days of wear. The clearance allows the pump to offer both tubed and tubeless infusion options, with a full commercial launch planned for the first half of 2027.
MetaVia Inc. reported third quarter 2026 financial results and provided a corporate update on its clinical pipeline, including positive Phase 1 interim data for DA-1726 in liver-related cardiometabolic diseases. The company also announced the appointment of Dr. Sarah Browne as Chief Medical Officer and plans to initiate a Phase 2 study in MetALD and ALD in the second half of 2027.
Term
Q3 2026
“The positive interim results from our Phase 1 Part 3B study of DA-1726, a novel oxyntomodulin (OXM) analog and dual GLP-1/glucagon receptor agonist, were recently highlighted in an oral presentation at the Precision Liver Symposium. We believe these findings provide important clinical support for DA-1726's potential to treat metabolic dysfunction and alcohol-associated liver disease (MetALD), as well as alcohol-associated liver disease (ALD).”
Hyung Heon Kim, President and Chief Executive Officer
“Last month, we also expanded our clinical leadership team with the appointment of Sarah Browne, M.D., as Chief Medical Officer. Sarah brings more than 20 years of experience spanning clinical development, regulatory science and clinical medicine, including leading the development of pemvidutide, a dual GLP-1/glucagon receptor agonist, through Phase 2 and establishing Phase 3 development strategies.”
Hyung Heon Kim, President and Chief Executive Officer
For the three months ended September 30, 2026, SPAR Group reported net revenue of $33.5 million and a small net income of $50,000, a significant recovery from the $8.8 million net loss in the prior year period. The company's balance sheet shows a substantial increase in accounts receivable and total liabilities, while stockholders' equity improved to $3.3 million from $0.6 million at the end of 2025.
SPAR Group reported its second consecutive quarter of profitability for the period ended September 30, 2026, despite a 19% year-over-year revenue decline to $33.5 million. The company highlighted improved gross margins of 18.9% and a significant 39% reduction in SG&A expenses following organizational streamlining. Additionally, the company announced a new three-year services agreement with a national retailer set to begin in 2027.
Term
Q3 2026
“I am pleased with our progress in returning to profitability for the second consecutive quarter. Although lower remodel activity year over year impacted revenue in the U.S., sales growth in Canada and our continued focus on higher-quality revenue drove continued profitability, resulting in positive net income, stronger gross margins year on year, and a 47% increase in Adjusted EBITDA on a year-to-date basis.”
William Linnane, President and Chief Executive Officer of SPAR Group
“Our third quarter financial performance reflects continued progress against our strategic and financial objectives. Gross margin expanded to 18.9%, notwithstanding lower U.S. revenue, while disciplined cost management drove SG&A expenses down 39% from the prior year.”
Steven Hennen, Chief Financial Officer of SPAR Group
Gary Merrill is resigning as CFO of Commvault Systems effective November 30, 2026, to pursue an opportunity at another public company. Danielle Abrahamsen, the company's current Chief Accounting Officer, has been appointed Interim CFO effective December 1, 2026, while a search for a permanent successor is conducted. The company also appointed Stan Zlotsky as Senior Vice President, Finance and reaffirmed its Q3 and FY2027 financial guidance.
Katapult Holdings reported a net income of $51.3 million for the nine months ended September 30, 2026, a significant improvement from the prior year, driven by a 23.8% increase in total revenues to $1.62 billion. The company's balance sheet expanded substantially following a reverse merger, with total assets growing from $1.4 billion to $3.1 billion and cash reserves increasing to $261.0 million.
Loop Industries received a deficiency notice from Nasdaq on November 9, 2026, for failing to maintain the minimum Market Value of Publicly Held Shares (MVPHS) of $15 million for 30 consecutive business days. The company has 180 calendar days, until May 10, 2027, to regain compliance by maintaining a MVPHS of at least $15 million for ten consecutive business days. The notice does not have an immediate effect on the listing of the company's common stock.
Indaptus Therapeutics reported a net loss of $5.38 million for the nine months ended September 30, 2026, a significant reduction from the $12.74 million loss in the prior year period. The company's cash position strengthened to $26.60 million following significant common stock issuances and preferred stock conversions, while operating expenses decreased across both R&D and G&A categories.
The Goodyear Tire & Rubber Company has called for the redemption of $700 million in aggregate principal amount of its 4.875% Senior Notes due 2027. The redemption is scheduled for December 15, 2026, at a price equal to 100% of the principal amount plus accrued and unpaid interest.
BIO-key International reported Q3 2026 financial results, highlighted by a 39% increase in software license fee revenue to $1.3 million and a gross margin improvement to 90%. The company narrowed its quarterly net loss to $0.89 million and retired its remaining outstanding debt, leaving the firm effectively debt-free.
Term
Q3 2026
“Our Q3’26 results reflect the building strength of our core software business. Software license fee revenue grew 39% in Q3’26, offsetting variability in our more episodic hardware and services revenue and lifting gross margin to 90% from 77% a year ago.”
Mike DePasquale, CEO
“Year to date we have grown revenue by 14%, reduced our net loss by 42% and we retired our remaining note outstanding leaving us effectively debt free.”
Perspective Therapeutics CMO Markus Puhlmann Buys $29.6K of Stock
Markus Puhlmann, CMO, bought 35,000 shares of Perspective Therapeutics, Inc. at $0.8447 a share, worth $29.6K in total on Nov 12, 2026. Shares held after the trade: 178,542 (+24.4%).
James Hardie Industries Insider Jesse G. Singh Sells $720K of Stock
Jesse G. Singh sold 25,000 shares of James Hardie Industries plc at $28.82 a share, worth $720K in total on Nov 11, 2026. Shares held after the trade: 333,797 (-7.0%).
NXP Semiconductors EVP, Chief Sales Officer Andrew Hardy Sells $438K of Stock
Andrew Hardy, EVP, Chief Sales Officer, sold 1,643 shares of NXP Semiconductors N.V. at $266.49 a share, worth $438K in total on Nov 11, 2026. Shares held after the trade: 4,064 (-28.8%).
Prospect Capital CEO John F. Barry Buys $6.05M of Stock
John F. Barry, CEO, bought 4,014,895 shares of Prospect Capital Corp at $1.51 to $1.51 a share (average $1.51) in 2 transactions, worth $6.05M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 95,808,672 (+1.5%).
Cineverse Corp. reported a significant revenue increase to $25.96 million for the quarter ended September 30, 2026, compared to $12.36 million in the prior year, driven by business growth and acquisition-related fair value adjustments. The company achieved a net income of $3.25 million for the quarter, a substantial improvement from a net loss of $5.55 million in the same period of 2025.
FRP Holdings, Inc. reported a net loss of $1.11 million for the nine months ended September 30, 2026, compared to a net income of $2.95 million in the prior year period. The decline was driven by increased general and administrative expenses and higher equity losses from joint ventures, despite a slight increase in total revenues to $32.64 million.
Benitec Biopharma reported a net loss of $12.9 million for the quarter ended September 30, 2026, compared to $9.0 million in the prior year period, primarily driven by a significant increase in research and development expenses for their BB-301 program. The company maintained a strong liquidity position with $176.4 million in cash and cash equivalents to fund ongoing clinical development.